Week In Review: Korea's Hanmi Signs $4.2 Billion Deal With Sanofi

Hanmi Pharma of Korea out-licensed global rights for three long-acting diabetes drugs to Sanofi in a deal worth $4.2 billion. Hanmi will receive $435 million upfront and up to $3.8 billion in milestones plus royalties on sales.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.